Dawn R. Mattoon
Amministratore Delegato presso Mercy Bioanalytics, Inc.
Posizioni attive di Dawn R. Mattoon
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Mercy Bioanalytics, Inc.
 Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | Direttore/Membro del Consiglio | 15/02/2023 | - |
| Amministratore Delegato | 15/02/2023 | - | |
| Direttore operativo | 11/07/2022 | 15/02/2023 |
Storia della carriera di Dawn R. Mattoon
Precedenti posizioni note di Dawn R. Mattoon
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| QUANTERIX CORPORATION | Direttore Tecnico/Scientifico/R&S | 01/02/2018 | - |
| Corporate Officer/Principal | 01/02/2018 | - | |
Cell Signaling Technology, Inc.
 Cell Signaling Technology, Inc. Medical SpecialtiesHealth Technology Cell Signaling Technology, Inc. manufactures and distributes research tools for cell function and diseases. It offers primary antibodies, activators and inhibitors, buffers and dyes, cellsimple, and cytokines. The company was founded in 1999 and is headquartered in Danvers, MA. | Corporate Officer/Principal | 01/07/2014 | 01/02/2018 |
Formazione di Dawn R. Mattoon
| Yale University | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| QUANTERIX CORPORATION | Health Technology |
| Aziende private | 2 |
|---|---|
Cell Signaling Technology, Inc.
Cell Signaling Technology, Inc. Medical SpecialtiesHealth Technology Cell Signaling Technology, Inc. manufactures and distributes research tools for cell function and diseases. It offers primary antibodies, activators and inhibitors, buffers and dyes, cellsimple, and cytokines. The company was founded in 1999 and is headquartered in Danvers, MA. | Health Technology |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | Health Technology |
- Borsa valori
- Insiders
- Dawn R. Mattoon
- Esperienza